Boehringer Ingelheim expands oncology portfolio with T3 Pharma acquisition
Boehringer Ingelheim announced its acquisition of T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech company specializing in immuno-oncology, for up to 450 million CHF. T3 Pharma’s innovative technology uses live bacteria to deliver immune-modulating proteins directly to cancer cells, advancing cancer treatment methodologies. Enhancing Cancer Immunotherapy Treatments Despite the progress in cancer treatments, long-term remissions […]